147 related articles for article (PubMed ID: 26255947)
1. Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model.
Sun Y; Sun L; An Y; Shen X
Med Sci Monit; 2015 Aug; 21():2316-21. PubMed ID: 26255947
[TBL] [Abstract][Full Text] [Related]
2. Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways.
Lin J; Chen Y; Wei L; Hong Z; Sferra TJ; Peng J
Int J Oncol; 2013 Nov; 43(5):1666-74. PubMed ID: 24042330
[TBL] [Abstract][Full Text] [Related]
3. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Song EK; Tai WM; Messersmith WA; Bagby S; Purkey A; Quackenbush KS; Pitts TM; Wang G; Blatchford P; Yahn R; Kaplan J; Tan AC; Atreya CE; Eckhardt G; Kelley RK; Venook A; Kwak EL; Ryan D; Arcaroli JJ
Int J Cancer; 2015 Apr; 136(8):1967-75. PubMed ID: 25242168
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
[TBL] [Abstract][Full Text] [Related]
5. Scutellaria barbata D. Don inhibits tumor angiogenesis via suppression of Hedgehog pathway in a mouse model of colorectal cancer.
Wei L; Lin J; Xu W; Cai Q; Shen A; Hong Z; Peng J
Int J Mol Sci; 2012; 13(8):9419-9430. PubMed ID: 22949805
[TBL] [Abstract][Full Text] [Related]
6. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
7. Hedyotis diffusa Willd extract suppresses Sonic hedgehog signaling leading to the inhibition of colorectal cancer angiogenesis.
Lin J; Wei L; Shen A; Cai Q; Xu W; Li H; Zhan Y; Hong Z; Peng J
Int J Oncol; 2013 Feb; 42(2):651-6. PubMed ID: 23291612
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
Scott AJ; Arcaroli JJ; Bagby SM; Yahn R; Huber KM; Serkova NJ; Nguyen A; Kim J; Thorburn A; Vogel J; Quackenbush KS; Capasso A; Schreiber A; Blatchford P; Klauck PJ; Pitts TM; Eckhardt SG; Messersmith WA
Mol Cancer Ther; 2018 Oct; 17(10):2112-2122. PubMed ID: 30026382
[TBL] [Abstract][Full Text] [Related]
9. Patrinia scabiosaefolia inhibits colorectal cancer growth through suppression of tumor angiogenesis.
Chen L; Liu L; Ye L; Shen A; Chen Y; Sferra TJ; Peng J
Oncol Rep; 2013 Sep; 30(3):1439-43. PubMed ID: 23820929
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein.
Xiang QF; Zhang DM; Wang JN; Zhang HW; Zheng ZY; Yu DC; Li YJ; Xu J; Chen YJ; Shang CZ
Liver Int; 2015 Mar; 35(3):1010-23. PubMed ID: 24621440
[TBL] [Abstract][Full Text] [Related]
12. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
[TBL] [Abstract][Full Text] [Related]
13. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.
Navis AC; Bourgonje A; Wesseling P; Wright A; Hendriks W; Verrijp K; van der Laak JA; Heerschap A; Leenders WP
PLoS One; 2013; 8(3):e58262. PubMed ID: 23484006
[TBL] [Abstract][Full Text] [Related]
14. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
16. Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways.
Shen A; Lin J; Chen Y; Lin W; Liu L; Hong Z; Sferra TJ; Peng J
Oncol Rep; 2013 Oct; 30(4):1701-6. PubMed ID: 23843018
[TBL] [Abstract][Full Text] [Related]
17. Oleanolic acid inhibits colorectal cancer angiogenesis in vivo and in vitro via suppression of STAT3 and Hedgehog pathways.
Li L; Lin J; Sun G; Wei L; Shen A; Zhang M; Peng J
Mol Med Rep; 2016 Jun; 13(6):5276-82. PubMed ID: 27108756
[TBL] [Abstract][Full Text] [Related]
18. Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice.
Yoshiji H; Yoshii J; Kuriyama S; Ikenaka Y; Noguchi R; Yanase K; Namisaki T; Kitade M; Yamazaki M; Fukui H
Oncol Rep; 2005 Jul; 14(1):213-8. PubMed ID: 15944792
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]